Menu Search
Equities

Hemogenyx Pharmaceuticals PLC

5HU:FRA

Hemogenyx Pharmaceuticals PLC

Actions
  • Price (EUR)0.0105
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-56.25%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 08:38 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. It is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, with bone marrow or hematopoietic stem cell transplants, and with viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HEMO-CAR-T, is therapy for the treatment of AML in which a patient’s own T-cells, a type of immune cell, are modified to recognize and kill the patient’s cancer cells. CBR is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-6.69m
  • Incorporated2013
  • Employees17.00
  • Location
    Hemogenyx Pharmaceuticals PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
  • Websitehttps://hemogenyx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.